

Title (en)  
7-AZAINDOLES AND USE THEREOF AS THERAPEUTIC AGENTS

Title (de)  
7-AZAINDOLE UND DEREN VERWENDUNG ALS THERAPEUTIKA

Title (fr)  
7-AZAINDOLES ET LEUR UTILISATION COMME PRODUITS THERAPEUTIQUES

Publication  
**EP 1613627 A1 20060111 (DE)**

Application  
**EP 04729102 A 20040423**

Priority

- EP 2004004339 W 20040423
- DE 10318610 A 20030424

Abstract (en)  
[origin: WO2004094416A1] The invention relates to substituted 7-azaindoles of formula (I), a method for the production thereof, pharmaceutical preparations comprising said compounds and the pharmaceutical use of said compounds which are inhibitors of phosphodiesterase 4, as active substances in the treatment of diseases which can be influenced by said inventive compounds by means of an inhibition of phosphodiesterase 4-activity, especially in immunocompetent cells (for example, macrophages and lymphocytes).

IPC 1-7  
**C07D 471/04**; **A61K 31/437**; **A61P 35/00**

IPC 8 full level  
**A61P 35/00** (2006.01); **C07D 471/04** (2006.01)

CPC (source: EP KR US)  
**A61P 1/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/04** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/36** (2017.12 - EP); **A61P 27/14** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 33/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 471/04** (2013.01 - EP KR US); **C07D 471/12** (2013.01 - KR)

Citation (search report)  
See references of WO 2004094416A1

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2004094416 A1 20041104**; AR 044080 A1 20050824; AU 2004232483 A1 20041104; AU 2004232483 B2 20100819; BR PI0409790 A 20060530; CA 2523063 A1 20041104; CA 2523063 C 20111206; CN 100475814 C 20090408; CN 1805960 A 20060719; DE 10318610 A1 20041111; EP 1613627 A1 20060111; JP 2006524209 A 20061026; KR 20060021830 A 20060308; MX PA05011439 A 20051212; NO 20055515 D0 20051122; NO 20055515 L 20060124; NZ 543700 A 20090731; RU 2005136434 A 20060327; RU 2349592 C2 20090320; TW 200505916 A 20050216; TW I365187 B 20120601; UA 82227 C2 20080325; US 2004224971 A1 20041111; US 2007161671 A1 20070712; US 7211583 B2 20070501; US 7947705 B2 20110524; ZA 200508321 B 20061025

DOCDB simple family (application)  
**EP 2004004339 W 20040423**; AR P040101395 A 20040423; AU 2004232483 A 20040423; BR PI0409790 A 20040423; CA 2523063 A 20040423; CN 200480016650 A 20040423; DE 10318610 A 20030424; EP 04729102 A 20040423; JP 2006505246 A 20040423; KR 20057020073 A 20051021; MX PA05011439 A 20040423; NO 20055515 A 20051122; NZ 54370004 A 20040423; RU 2005136434 A 20040423; TW 93111119 A 20040421; UA 2005009797 A 20040423; US 71446607 A 20070306; US 82613604 A 20040416; ZA 200508321 A 20051014